Tango Therapeutics reports Q4 2021 net loss $22.0M; cash $485.3M; TNG908 Fast Track

Tango Therapeutics, Inc.

Net loss Q4 2021: $22.0M ($0.25/share) vs $8.9M ($0.22/share) in Q4 2020; full year $58.2M ($0.94/share).
Revenue Q4 2021: $5.7M vs $9.1M in Q4 2020; full year $37.0M vs $7.7M in 2020 (Gilead amendment effect).
Cash, equivalents & marketable securities: $485.3M as of Dec 31, 2021, expected to fund operations into H2 2024.
TNG908 (PRMT5 inhibitor) granted FDA Fast Track; Phase 1/2 trial expected to start Q2 2022.
Target 3 and USP1 development candidates expected Q2 and H2 2022, respectively; leadership team expanded.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.